Literature DB >> 623981

Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.

H E Webb, S W Oaten, C P Pike.   

Abstract

Six patients with malignant effusions, five from adenocarcinomas and one from a melanoma, were treated by intrapleural or intraperitoneal Corynebacterium parvum. In each case there was a definite reduction in the effusions with a significant decrease in the number of malignant cells; in most cases the effusions stopped completely. Although none of the patients lived for more than a year after treatment, they were undoubtedly more comfortable, as they no longer required frequent paracentesis. In some cases the patients lived for longer than originally expected in a state in which the quality of life was acceptable.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623981      PMCID: PMC1602912          DOI: 10.1136/bmj.1.6109.338

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax).

Authors:  C M Laroche; M Britton
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

3.  Intrapleural Corynebacterium parvum for malignant pleural effusions.

Authors:  R Felletti; C Ravazzoni
Journal:  Thorax       Date:  1983-01       Impact factor: 9.139

Review 4.  Cancer immunotherapy.

Authors:  S P Richman; J U Gutterman; E M Hersh
Journal:  Can Med Assoc J       Date:  1979-02-03       Impact factor: 8.262

5.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

6.  Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions.

Authors:  J W Millar; A M Hunter; N W Horne
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.